Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage drug development company focused on novel oral therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD). The BLTE news feed highlights how the company advances its lead candidate, Tinlarebant, through late-stage clinical trials and global regulatory pathways.
Investors and observers following Belite Bio’s news can track updates on pivotal clinical programs such as the Phase 3 DRAGON and DRAGON II trials in adolescent STGD1 patients and the Phase 3 PHOENIX trial in GA. Company announcements cover milestones like completion of trial enrollment, last subject visits, and the release of topline efficacy and safety data, including the reported positive Phase 3 DRAGON results showing reduced lesion growth in STGD1.
The BLTE news stream also features information on regulatory interactions and designations for Tinlarebant, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, Orphan Drug, and Sakigake (Pioneer Drug) designations, as well as decisions by agencies such as China’s NMPA and the UK’s MHRA to accept applications based on interim Phase 3 data. In addition, readers can follow Belite Bio’s capital markets activities, including registered direct offerings, private placements, and underwritten public offerings of American Depositary Shares that the company describes as supporting clinical development and commercialization preparation.
By reviewing Belite Bio news, users can see how clinical data, regulatory developments, and financing events shape the company’s efforts to develop Tinlarebant as a potential oral treatment option for inherited and degenerative retinal diseases.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm, announced its participation in the Benchmark’s 4th Annual Healthcare House Call Investor Conference. The event, set for May 21 and 22, 2024, will be held virtually. Belite Bio's executive management will host a fireside chat at 3:00 pm ET on May 21, 2024. The company focuses on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Belite Bio (NASDAQ: BLTE) announced its Q1 2024 results and provided a corporate update. The company highlighted positive data from its Phase 2 trial of Tinlarebant in STGD1 patients, showing sustained lower atrophic lesion growth. Tinlarebant is also being evaluated in ongoing Phase 3 trials (DRAGON and PHOENIX) for STGD1 and GA, respectively. Interim data from these trials are expected in Q4 2024. Financially, Belite raised $25 million through a direct offering and reported a net loss of $7.9 million for Q1 2024, up from $6.9 million in Q1 2023. The company held $95.5 million in cash and U.S. treasury bills as of March 31, 2024.
Belite Bio, Inc. (NASDAQ: BLTE) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on May 20, 2024. The company will host a fireside chat at 3:30 pm ET, accessible via webcast on their investor relations website.
Belite Bio, Inc. (NASDAQ: BLTE) will host a webcast on May 14, 2024, to discuss the first quarter 2024 financial results and provide a business update. The company is a clinical-stage biopharmaceutical drug development company focused on degenerative retinal diseases. The webcast will be held at 4:30 p.m. Eastern Time.
Belite Bio, Inc. (BLTE) will participate in a Key Opinion Leader Webinar to discuss Stargardt Disease and Geographic Atrophy and share insights on Tinlarebant, a novel therapeutic. The webinar, moderated by Cantor Fitzgerald, will feature Dr. Michel Michaelides, a renowned expert. Tinlarebant is a promising treatment with Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Belite Bio presented additional analysis from a Phase 2 study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting. The 24-month trial showed promising results in slowing lesion growth and stabilizing visual acuity. Genetic profiling revealed that despite severe ABCA4 variants, 42% of treated subjects did not develop atrophic retinal lesions. A novel lesion size quantification method was able to detect atrophic lesions more accurately. The drug is now being evaluated in Phase 3 trials for Stargardt Disease and Geographic Atrophy.
Belite Bio presented promising data on Tinlarebant, an oral tablet aimed at slowing disease progression in patients with retinal diseases at ARVO 2024. The Phase 2 trial showed a significant reduction in atrophic lesion growth in STGD1 patients compared to standard treatment. Enrollment for Phase 3 trials is complete, with interim data expected in Q4 2024.
Summary not available.
Summary not available.
Summary not available.